A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sponsor: Peking Union Medical College Hospital
A PHASE1 clinical study on B-cell Non-Hodgkin Lymphoma, this trial is completed. The trial is conducted by Peking Union Medical College Hospital and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Not Yet Recruiting → Completed
-
Aug 2018 — Apr 2020 [monthly]
Not Yet Recruiting PHASE1
▶ Show 3 earlier versions
-
Jul 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Peking Union Medical College Hospital
- Shanghai AbelZeta Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .